-+ 0.00%
-+ 0.00%
-+ 0.00%

-- Bayer's Sevabertinib Wins China Approval for First-line HER2-Mutant Non-small Cell Lung Cancer

MT Newswires·11/04/2026 03:14:38
Listen to the news
03:14 AM EST, 11/04/2026 (MT Newswires) --